RedHill Biopharma's combo antibiotic for Helicobacter pylori infection met its main goal in a late-stage trial, putting the Israeli outfit in line for a sit-down with the FDA to plot a path to market.
San Diego-based Avalon Ventures has doubled up on its pipeline of programs being developed in partnership with GlaxoSmithKline. The venture group has launched three new companies, plucking new drug projects that range from cardiovascular disease, to cancer to a rare lysosomal storage disorder.
Johnson & Johnson has teamed up with Emulate to incorporate organ-on-a-chip technology into its R&D programs. The project will allow J&J to assess whether the technology can do a better job than animal models at assessing pulmonary thrombosis and predicting liver toxicity.
Bluebird bio took another step forward today in its carefully planned march toward a possible accelerated approval for its lead program, noting that their first sickle cell disease patient has been responding remarkably well to their therapy while adding evidence of improved durability in responses for beta-thalassemia.
A dual-chambered leadless pacer would earn billions in revenue and overtake the entire market, but has proven elusive due to technical challenges. A North Dakota State University team has another idea for improvement.
A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.
Agios Pharmaceuticals' lead cancer drug extended its streak of promising clinical results, racking up remissions in an expanded Phase I trial as the company prepares for late-stage testing.
Twist Bioscience is set to grow its headcount by 50% after it raised $37 million from Illumina and other investors to move its DNA synthesis technology toward commercialization. And IT hires feature heavily in the startup's plans, with half of the current job openings relating to bioinformatics, Python databases and other niches in the field.
San Diego's BioAtla has raised $30 million in equity from undisclosed Chinese investors, cash that will help push its pipeline of large-molecule treatments.
Antiviral drug developer ContraVir Pharmaceuticals is working with ImageIQ on its Phase III program for a new shingles treatment, tapping the company for its imaging expertise.